olmesartan medoxomil/amlodipine/hydrochlorothiazide krka 40 mg/5 mg/25 mg film-coated tablets
krka, d.d., novo mesto - olmesartan medoxomil; amlodipine; hydrochlorothiazide - film-coated tablet - 40/5/25 milligram(s) - olmesartan medoxomil, amlodipine and hydrochlorothiazide
olmesartan medoxomil/amlodipine/hydrochlorothiazide krka 20 mg/5 mg/12.5 mg film-coated tablets
krka, d.d., novo mesto - olmesartan medoxomil; amlodipine; hydrochlorothiazide - film-coated tablet - 20/5/12.5 milligram(s) - olmesartan medoxomil, amlodipine and hydrochlorothiazide
olmesartan medoxomil/amlodipine/hydrochlorothiazide krka 40 mg/10 mg/12.5 mg film-coated tablets
krka, d.d., novo mesto - olmesartan medoxomil; amlodipine; hydrochlorothiazide - film-coated tablet - 40/10/12.5 milligram(s) - olmesartan medoxomil, amlodipine and hydrochlorothiazide
amlodipine and olmesartan medoxomil- amlodipine besylate and olmesartan medoxomil tablet, film coated
sun pharmaceutical industries, inc. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), olmesartan medoxomil (unii: 6m97xtv3hd) (olmesartan - unii:8w1iqp3u10) - amlodipine 5 mg - amlodipine and olmesartan medoxomil tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (cv) events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with amlodipine and olmesartan medoxomil tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pre
amlodipine and olmesartan medoxomil- amlodipine and olmesartan medoxomil tablet, film coated
apotex corp. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), olmesartan medoxomil (unii: 6m97xtv3hd) (olmesartan - unii:8w1iqp3u10) - amlodipine 5 mg - amlodipine and olmesartan medoxomil tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with amlodipine and olmesartan medoxomil tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure
amlodipine and olmesartan medoxomil- amlodipine and olmesartan medoxomil tablet, film coated
jubilant cadista pharmaceuticals inc. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), olmesartan medoxomil (unii: 6m97xtv3hd) (olmesartan - unii:8w1iqp3u10) - amlodipine 5 mg - amlodipine and olmesartan medoxomil tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with amlodipine and olmesartan medoxomil tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national hi
olmesartan medoxomil/amlodipine teva 20/5 mg/mg film coated tablet
teva b.v. - olmesartan medoxomil, amlodipine besilate - film coated tablet - 20/5 mg/mg - angiotensin ii antagonists and calcium channel blockers
olmesartan medoxomil/amlodipine teva 40/5 film coated tablet
teva b.v. - olmesartan medoxomil, amlodipine besilate - film coated tablet - 40/5 - angiotensin ii antagonists and calcium channel blockers
olmesartan medoxomil/amlodipine teva 40/10 film coated tablet
teva b.v. - olmesartan medoxomil, amlodipine besilate - film coated tablet - 40/10 - angiotensin ii antagonists and calcium channel blockers
olmesartan/ amlodipine
organon pharma pty ltd - olmesartan medoxomil, quantity: 40 mg; amlodipine besilate, quantity: 13.888 mg (equivalent: amlodipine, qty 10 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; pregelatinised maize starch; colloidal anhydrous silica; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - olmesartan/ amlodipine-myl is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.